F
Frédérique Penault-Llorca
Researcher at University of Auvergne
Publications - 392
Citations - 38820
Frédérique Penault-Llorca is an academic researcher from University of Auvergne. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 77, co-authored 357 publications receiving 32557 citations.
Papers
More filters
Journal ArticleDOI
Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013
A. Goldhirsch,E P Winer,A S Coates,R. D. Gelber,M Piccart-Gebhart,B. Thürlimann,H.-J. Senn,Kathy S. Albain,Fabrice Andre,Jonas Bergh,Hervé Bonnefoi,Denisse Bretel-Morales,Harold J. Burstein,Fatima Cardoso,M. Castiglione-Gertsch,Alan S. Coates,Marco Colleoni,Alberto Costa,Giuseppe Curigliano,Nancy E. Davidson,Angelo Di Leo,Bent Ejlertsen,John F. Forbes,Richard D. Gelber,Michael Gnant,Aron Goldhirsch,Pamela J. Goodwin,Paul E. Goss,Jay R. Harris,Daniel F. Hayes,Clifford A. Hudis,James N. Ingle,Jacek Jassem,Zefei Jiang,Per Karlsson,Sibylle Loibl,Monica Morrow,Moïse Namer,C. Kent Osborne,Ann H. Partridge,Frédérique Penault-Llorca,Charles M. Perou,Martine Piccart-Gebhart,Kathleen I. Pritchard,Emiel J. Th. Rutgers,Felix Sedlmayer,Vladimir Semiglazov,Z Shao,Ian E. Smith,Beat Thürlimann,Masakazu Toi,Andrew Tutt,Michael Untch,Giuseppe Viale,Toru Watanabe,Nicholas Wilcken,Eric P. Winer,William C. Wood +57 more
TL;DR: The 13th St Gallen International Breast Cancer Conference (2013) Expert Panel reviewed and endorsed substantial new evidence on aspects of the local and regional therapies for early breast cancer, supporting less extensive surgery to the axilla and shorter durations of radiation therapy.
Journal ArticleDOI
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Elżbieta Senkus,Stella Kyriakides,Frédérique Penault-Llorca,P.M. Poortmans,Alexander J. Thompson,Sophia Zackrisson,Fatima Cardoso +6 more
TL;DR: This work presents the results of a meta-analysis conducted at the 2016 European Oncology and Radiotherapy Guidelines Working Group (ESMO) workshop on breast cancer diagnosis and prognosis of women with atypical central giant cell granuloma (CGM) who have previously had surgery.
Journal ArticleDOI
KRAS Mutation Status Is Predictive of Response to Cetuximab Therapy in Colorectal Cancer
Astrid Lièvre,Jean-Baptiste Bachet,Delphine Le Corre,Valérie Boige,Bruno Landi,Jean-François Emile,Jean-François Côté,Gorana Tomasic,Christophe Penna,Michel Ducreux,Philippe Rougier,Frédérique Penault-Llorca,Pierre Laurent-Puig +12 more
TL;DR: KRAS mutations are a predictor of resistance to cetuximab therapy and are associated with a worse prognosis, and the EGFR amplification, which is not as frequent as initially reported, is also associated with response to this treatment.
Journal ArticleDOI
The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014
Roberto Salgado,Carsten Denkert,Sandra Demaria,Nicolas Sirtaine,Frederick Klauschen,Giancarlo Pruneri,Stephan Wienert,G. Van den Eynden,Frederick L. Baehner,Frédérique Penault-Llorca,E. A. Perez,E. A. Thompson,William Fraser Symmans,Andrea L. Richardson,Jane E. Brock,Carmen Criscitiello,Helen Bailey,Michail Ignatiadis,Giuseppe Floris,Joseph A. Sparano,Zuzana Kos,Torsten O. Nielsen,David L. Rimm,Kimberly H. Allison,Jorge S. Reis-Filho,Sibylle Loibl,Christos Sotiriou,Giuseppe Viale,Sunil S. Badve,Sylvia Adams,Karen Willard-Gallo,Sherene Loi +31 more
TL;DR: Current data on the clinical validity and utility of TILs in BC are reviewed in an effort to foster better knowledge and insight in this rapidly evolving field, and to develop a standardized methodology for visual assessment on H&E sections.
Journal ArticleDOI
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis
Wendy De Roock,Bart Claes,David Bernasconi,Jef De Schutter,Bart Biesmans,George Fountzilas,Konstantine T. Kalogeras,Vassiliki Kotoula,Demetris Papamichael,Pierre Laurent-Puig,Frédérique Penault-Llorca,Philippe Rougier,Bruno Vincenzi,Daniele Santini,Giuseppe Tonini,Federico Cappuzzo,Milo Frattini,Francesca Molinari,Piercarlo Saletti,Sara De Dosso,Miriam Martini,Alberto Bardelli,Salvatore Siena,Andrea Sartore-Bianchi,Josep Tabernero,Teresa Macarulla,Frédéric Di Fiore,Alice Gangloff,Fortunato Ciardiello,Per Pfeiffer,Camilla Qvortrup,Tine Plato Hansen,Eric Van Cutsem,Hubert Piessevaux,Diether Lambrechts,Mauro Delorenzi,Mauro Delorenzi,Sabine Tejpar +37 more
TL;DR: This is the largest cohort to date of patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab plus chemotherapy in the pre-KRAS selection era and confirmed that, if KRAS is not mutated, assessing BRAF, NRAS, and PIK3CA population response rates confirmed that.